Casale R, Giorgi I, Guarnaschelli C
Int J Clin Pharmacol Res. 1984;4(4):313-9.
With a view to determining the efficacy of Teproside versus placebo in patients affected with cerebrovascular disease, 30 subjects, selected at the Montescano Medical Rehabilitation Centre, were randomly divided into two groups of 15 subjects each. After a two-week wash-out period, the first group was treated with placebo and the second with vincamine teprosilate (Teproside) at 120 mg daily, both for a period of 90 days. The assessment of each patient took place in two stages, one at the beginning and one at the end of treatment. It was performed according to both clinical criteria (including an interview with the patient and his family) and neuro-psychological criteria (memory tests, perceptive-spatial and logical functions tests). The data obtained showed a significant improvement of the behavioural performance, the mnemonic ability and the perceptive-motor activity in the Teproside group treated.
为了确定特普罗苷与安慰剂对脑血管疾病患者的疗效，在蒙特斯卡诺医学康复中心选取了30名受试者，随机分为两组，每组15名。经过两周的洗脱期后，第一组接受安慰剂治疗，第二组接受每天120毫克的长春胺特普罗酯（特普罗苷）治疗，为期90天。对每位患者的评估分两个阶段进行，一个在治疗开始时，一个在治疗结束时。评估依据临床标准（包括与患者及其家属面谈）和神经心理学标准（记忆测试、感知空间和逻辑功能测试）进行。所获得的数据显示，接受特普罗苷治疗的组在行为表现、记忆能力和感知运动活动方面有显著改善。
